Bladder cancer was the most important reason of cancer-related death around the world, and urgently requires new therapeutic methods targeting the malignant tumor. There are many reports that the long noncoding RNAs are participated in different cancers, however, limited data are found between the long noncoding RNAs and bladder cancer. Previous studies have indicated that lncRNAs play vital roles in gene regulatory processes which could influence carcinoma progression.It is well known that lncRNAs can't code proteins, however, controlling transcription was found in the life process.In the current study,we firstly reported that NEAT1 was consistently up-regulated in bladder cancer tissues compared to the matched tissues and bladder cancer cell lines compared to the normal bladder epithelial cell and the expression level of the NEAT1 in bladder cancer tissues is closely related to its clinical pathologic grade and TNM phase. Cell proliferation inhibition, cell migration suppression and apoptosis induction were detected by knockdown NEAT1. However, it is imperative that this hypothesis is further tested through. In conclusion, NEAT1 may play oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. Our finding provides a new insight into the role of the LncRNA NEAT1 in the bladder cancer.

Hypercholesterolemia is the main cause of cardiovascular disease worldwide, and the regulation of cholesterol homeostasis is essential for human health. Lactobacillus is present in large quantities in the human intestine. As the normal flora in the gut, lactobacillus plays an important role in regulating metabolism in the human body. Lactobacillus can regulate the cholesterol content by regulating the expression of genes involved in cholesterol synthesis, metabolism, and absorption. This article reviews the biological effects and mechanisms of lactobacillus that mediate the expression of NPC1L1, CYP7A1, ABCG5, ABCG8, and other genes to inhibit cholesterol absorption, and discusses the mechanism of reducing cholesterol by lactobacillus in cells in vitro, to provide a theoretical basis for the development and utilization of lactobacillus resources.

The correlation between miR-200 family overexpression and cancer prognosis remains controversial. Therefore, we conducted a systematic review and meta-analysis by searching PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), and China National Knowledge Infrastructure (CNKI) to identify eligible studies. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the correlations. Additionally, different subgroup analyses and publication bias test were performed. Eventually, we analyzed 23 articles that included five tumor types and 3038 patients. Consequently, high expression of miR-200 family in various tumors was associated with unfavorable overall survival (OS) in both univariate (HR = 1.32, 95% CI: 1.14–1.54, P < 0.001) and multivariate (HR = 1.32, 95% CI: 1.16–1.49, P < 0.001) analyses. Likewise, a similar result was found in different subgroups of the patient source, cancer type, test method, sample source, miR-200 component, and sample size. However, no association of miR-200 family was detected with recurrence- or relapse-free survival (RFS) (univariate: HR = 1.02, 95% CI: 0.96–1.09, P = 0.47; multivariate: HR = 1.07, 95% CI: 1.00–1.14, P = 0.07), progression-free survival (PFS) (univariate: HR = 0.96, 95% CI: 0.54–1.70, P = 0.88; multivariate: HR = 1.17, 95% CI: 0.86–1.61, P = 0.32), and disease-free survival (DFS) (univariate: HR = 0.90, 95% CI: 0.74–1.09, P = 0.29; multivariate: HR = 0.98, 95% CI: 0.68–1.41, P = 0.90). Our findings have provided convincing evidence that miR-200 family overexpression suggested poor prognosis of various cancer types, which efforts may raise the potential use of miR-200 family for cancer prognosis in clinical practice.